Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00365027
Recruitment Status : Withdrawn (Enrollment difficulties)
First Posted : August 16, 2006
Last Update Posted : September 4, 2015
Information provided by:
HaEmek Medical Center, Israel

Brief Summary:
It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.

Condition or disease Intervention/treatment Phase
Ovarian Hyperstimulation Syndrome Infertility Drugs Female Procedure: Delayed embryo transfer Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Implantation rate per transfer
  2. Pregnancy rate per embryo transfer
  3. Implantation rate per IVF cycle
  4. Pregnancy rate per IVF cycle

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation

Exclusion Criteria:

  • Patient's refusal to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00365027

Sponsors and Collaborators
HaEmek Medical Center, Israel
Study Chair: Eliezer Shalev HaE'mek medical center Identifier: NCT00365027     History of Changes
Other Study ID Numbers: 5040706
First Posted: August 16, 2006    Key Record Dates
Last Update Posted: September 4, 2015
Last Verified: September 2015

Keywords provided by HaEmek Medical Center, Israel:
GNRH agonist
ovarian hyperstimulation syndrome
Embryo cryopreservation

Additional relevant MeSH terms:
Ovarian Hyperstimulation Syndrome
Genital Diseases, Male
Genital Diseases, Female
Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Endocrine System Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action